An observational study in Systemic Sclerosis (SSc) and GERD (Gastroesophageal Reflux Disease), sponsored by Hospital Universitari Vall d'Hebron Research Institute. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational
The goal of this observational study is to learn about the mechanisms of gastroesophageal reflux disease (GERD) in patients with systemic sclerosis (SSc) who continue to experience reflux symptoms despite treatment with proton pump inhibitors (PPIs). The main question it aims to answer is:
What are the underlying gastrointestinal mechanisms contributing to PPI-refractory reflux symptoms in patients with SSc?
Participants with a confirmed diagnosis of SSc and persistent reflux symptoms despite PPI therapy will undergo standard-of-care diagnostic tests, including high-resolution esophageal manometry and pH-impedance monitoring. Clinical data and test results will be collected and analyzed to identify patterns of motility dysfunction and reflux characteristics associated with refractory symptoms.
Background:
Gastroesophageal reflux disease (GERD) is one of the most frequent gastrointestinal manifestations in patients with systemic sclerosis (SSc). However, a significant proportion of these patients experience symptoms that are refractory to treatment with proton pump inhibitors (PPIs), suggesting the involvement of underlying pathophysiological mechanisms that are not yet fully defined. Motor dysfunction in other segments of the gastrointestinal tract may contribute to this refractoriness, but studies addressing this in the SSc population have been limited. Currently, there are no personalized diagnostic algorithms that integrate symptoms, objective motility findings, and clinical characteristics in patients with SSc and GERD. Our goal is to identify the mechanisms associated with the severity of PPI-refractory GERD in SSc and to develop a practical and cost-effective diagnostic model based on objective data to enable personalized medicine.
Hypothesis:
PPI-refractory GERD in patients with systemic sclerosis can be assessed more sensitively and accurately through objective evaluation of motility across different gastrointestinal organs.
Objective:
To assess the pathophysiological mechanisms associated with the severity of refractory GERD in patients with SSc using objective motility tests and clinical markers, and to develop a diagnostic algorithm to guide personalized treatment based on the organ affected.
Methods:
This is a prospective clinical cohort study. Patients with SSc and symptoms of GERD refractory to PPIs will be included. Clinical, immunological, and demographic variables will be collected. Esophageal symptoms and quality-of-life impact will be assessed using validated questionnaires. Advanced gastrointestinal motility tests (gastric emptying scintigraphy and high-resolution intestinal manometry) will be performed to evaluate mechanisms associated with reflux severity (presence of erosive esophagitis and esophageal acid exposure).
Relevance:
This study addresses a common clinical challenge in patients with SSc: the persistence of GERD symptoms despite acid-suppressive treatment with PPIs. This project proposes to elucidate the pathophysiological mechanisms associated with GERD severity using motility tests available in clinical practice, and to develop a personalized approach based on objective motility assessment. This will allow the identification of the underlying mechanisms of treatment-refractory GERD and, in the future, the evaluation of targeted therapies addressing the associated dysmotility. The development of a diagnostic algorithm will support clinical decision-making, promote rational use of invasive tests, and optimize patient management, with a potential impact on improving quality of life and healthcare efficiency.
Patients with systemic sclerosis and PPI-refractory reflux symptoms who are members of the Spanish Association of Patients with Systemic Sclerosis and/or those recruited from outpatient clinics at participating centers.
Exclusion Criteria:
Severe pulmonary or cardiac disease requiring intravenous vasodilators, continuous oxygen therapy, or ventricular assist devices, preventing the performance of gastrointestinal motility tests.
Pregnancy at the time of evaluation or planned pregnancy during the duration of the study.
Neuromuscular disorders other than systemic sclerosis that may affect gastrointestinal motility.
Prior diagnosis of functional gastrointestinal disorders, such as irritable bowel syndrome or functional dyspepsia, that may interfere with the interpretation of results.
Study Subjects: Patients will be recruited from the outpatient clinics of the Autoimmune Diseases Unit or the Gastroenterology Department at the Vall d'Hebron University Hospital (HUVH), Barcelona. Inclusion Criteria: Diagnosis of systemic sclerosis according to the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria and/or LeRoy criteria. Age ≥ 18 years. Presence of gastroesophageal reflux symptoms, defined as heartburn and/or regurgitation occurring at least three times per week over the past three months, despite ongoing treatment with PPIs.
Other: educational healthcare intervention · Diagnostic Test: Objective assessment of GI motility · Diagnostic Test: Evaluation of GERD severity
This intervention will be applyed at the beginning of the study
Also known as: avoiding late dinners, not lying down for at least 2 hours after meals, avoiding tobacco and alcohol, avoiding large or high-fat meals
Objetive assessment of gastrointestinal dysmotility in GI organs (esophagus, stomach, small bowel) will be performed using state of the art tests.
Also known as: Gastric emptying test, Small bowel manometry, High-resolution esophageal manometry, Abdominal CT scan
Objective evaluation of GERD severity on PPI therapy will be performed.
Also known as: upper GI endoscopy (on PPI), pH-impedance monitoring (on PPI)
Prevalence of PPI-refractory GERD
The presence of erosive esophagitis B,C, or D on endoscopy, acid exposure time \> 4% or \> 80 reflux episodes, as per Lyon 2.0 criteria, will be considered refractory GERD.
Time frame: At the end of double PPI and health intervention period (8 - 12 weeks)
Gastrointestinal dysmotility associations
prevalence of delayed gastric emptying, esophageal dysmotility and small bowel dysmotility.
Time frame: After 8 weeks on double PPI therapy, during week 8 to 12.
No study locations are listed for this record.
Plan to share: Undecided
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute